PainReform Ltd. (NASDAQ:PRFX) today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit.
HERZLIYA, ISRAEL / ACCESSWIRE / September 9, 2020 / PainReform Ltd. (NASDAQ:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit. Each unit consisted of one Ordinary Share and one Warrant to purchase one Ordinary Share. The Ordinary Shares and Warrants were immediately separable from the units and were issued separately. The Ordinary Shares began trading on the Nasdaq Capital Market on September 1, 2020 under the symbol “PRFX”. The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $8.80 per share. PainReform received gross proceeds of approximately $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Maxim Group LLC and Joseph Gunnar & Co., LLC acted as joint book-runners for the offering.
PainReform has granted the underwriters a 45-day option to purchase up to an additional 375,000 Ordinary Shares and/or Warrants to purchase 375,000 Ordinary Shares, or any combination thereof, to cover over-allotments, if any.
The offering was conducted pursuant to the Company’s registration statement on Form F-1 (File No. 333-239576) previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any security in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About PainReform
PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com
SOURCE: PainReform Ltd.
View source version on accesswire.com:
https://www.accesswire.com/605428/PainReform-Announces-Closing-of-200-Million-Initial-Public-Offering
